Merck Serono identifies UK as personalised meds laggard
This article was originally published in Scrip
Makers of personalised cancer medicines trying to sell their products in the UK may be fighting a losing battle. A survey compiled by Merck Serono found that 75% of oncologists believe there are barriers preventing the use of personalised medicines within the UK's National Health Service.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.